

Hong Kong Public Offering – Yellow Form 香港公開發售 – 黃色申請表格

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant.

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的CCASS投資者參與者的香港發售股份,並直接存入中央結算及交收系統(「中央結算系統」),以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口,請用本表格。

NOTE: Unless defined herein, terms and expressions used in this Application Form have the same meanings as defined in the prospectus of Shanghai Pharmaceuticals Holding Co., Ltd. (the “Company”) dated May 6, 2011 (the “Prospectus”).

附註: 除本申請表格所界定者外,本申請表格所用的詞語及措辭與上海醫藥集團股份有限公司(「本公司」)於2011年5月6日刊發的招股說明書(「招股說明書」)所界定者具有相同涵義。

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for or in reliance upon the whole or any part of this Application Form.

香港聯合交易所有限公司、香港聯合交易所有限公司(「香港聯交所」)及香港中央結算有限公司(「香港結算」)對本申請表格的內容概不負責,對其準確性或完整性亦不發表任何聲明,並明確表示概不就因本申請表格全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。

A copy of this Application Form, together with a copy of each of the WHITE and GREEN Application Forms, the Prospectus and the other documents specified in the paragraph headed “Documents Delivered to the Registrar of Companies” in “Appendix XI – Documents Delivered to the Registrar of Companies and Available for Inspection” in the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong), The Securities and Futures Commission (the “SFC”) and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

本申請表格連同每份白色及綠色申請表格、招股說明書及招股說明書附錄(附錄十一—送呈公司註冊處處長及備查文件)內「送呈公司註冊處處長文件」一段所列的其他文件,已遵照香港法例第32章公司條例第342C條的規定,於香港公司註冊處註冊。證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對本申請表格的內容概不負責。

The information contained in this Application Form is not for publication, distribution or release, direct or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The H Shares mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”).

本申請表格所載資料,不為或向美國(包括其領土及屬地、美國各州及哥倫比亞特區)境內直接或間接刊發、分發或發售。於美國,該等資料並不構成或成為購買或認購證券的任何要約或邀請。本申請表格所述H股並不會及將不會根據1933年美國證券法(經修訂)(「美國證券法」)登記。

The H Shares may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. No public offering of the securities will be made in the United States.

除非已進行登記或已根據美國證券法的登記規定獲得豁免,否則將不會於美國發售或出售H股,亦不會於美國進行證券的公開發售。

Nothing in the Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful.

本申請表格或招股說明書的內容概不構成或提出呈出售、邀請要約購買或出售任何香港發售股份即屬違法之司法權區內作出有關呈出或邀請,亦不得在有關司法權區出售香港發售股份。



上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 664,214,000 H Shares (subject to the Over-Allotment Option)
Number of Hong Kong Offer Shares	: 33,210,800 H Shares (subject to adjustment)
Number of International Offer Shares	: 631,003,200 H Shares (subject to adjustment and the Over-Allotment Option)
Maximum Offer Price	: HK\$26.00 per Offer Share plus brokerage of 1%, SFC transaction levy of 0.003% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund on final pricing)
Nominal Value	: RMB1.00 per H Share
Stock Code	: 02607

全球發售

全球發售的發售股份數目	: 664,214,000股H股(視乎超額配售權而定)
香港發售股份數目	: 33,210,800股H股(可予調整)
國際發售股份數目	: 631,003,200股H股(可予調整及視乎超額配售權而定)
最高發售價格	: 每股發售股份26.00港元,另加1%經紀佣金、0.003%證監會交易費及0.005%香港聯交所交易費(須於申請時以港元繳足,多收款項於最終定價後可予退還)
面值	: 每股H股人民幣1.00元
股份代號	: 02607

Application Form 申請表格

Applications will be accepted until 12:00 noon on Thursday, May 12, 2011.
You must read the conditions and instructions attached to this Application Form.
To be valid, you must complete all applicable parts of this Application Form.
Please write clearly in ink.

截止接受申請時間為
2011年5月12日(星期四)中午十二時正。
閣下須細閱本申請表格所附載的條件及指示。
本申請表格各適用部分必須全部以墨水筆清楚填妥,方為有效。

To: Shanghai Pharmaceuticals Holding Co., Ltd.
Goldman Sachs (Asia) L.L.C.
Deutsche Bank AG, Hong Kong Branch
Credit Suisse (Hong Kong) Limited
The Hong Kong Underwriters

I/We:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association;
- enclose payment in full for the Hong Kong Offer Shares applied for, including 1% brokerage, 0.003% SFC transaction levy and 0.005% Hong Kong Stock Exchange trading fee;
- undertake and agree to accept the Hong Kong Offer Shares applied for, or any lesser number allotted to me/us under this application;
- declare that this is the only application made and the only application intended by me/us to be made whether on a WHITE or YELLOW Application Form or by giving electronic application instructions to HKSCC via CCASS and/or to the designated White Form eIPO Service Provider under the White Form eIPO service (www.eipo.com.hk) to be/for me/us or the person for whose benefit I am/we are applying;
- undertake and confirm that I/we and the person for whose benefit I am/we are applying have not applied for, taken up or indicated an interest in, or received or been placed or allocated (including conditionally and/or provisionally) and will not apply for, take up or indicate an interest in any International Offering Shares under the International Offering;
- understand that this declaration and representation will be relied upon by the Company and the Joint Bookrunners in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application and that I/we may be prosecuted if I/we make a false declaration;
- authorise the Company to place the name of HKSCC Nominees on the register of members of the Company as the holder of any Hong Kong Offer Shares to be issued to me/us or to the designated H Share certificate directly into CCASS for the credit of my/our CCASS Investor Participant stock account or the stock account of my/our designated CCASS Participant as instructed by me/us;
- request that any refund cheques be made payable to me, or in the case of joint applicants, to the first-named of us in this Application Form, and (subject to the terms and conditions set out in this Application Form and in the Prospectus) to send any refund cheques(s) by ordinary post at my/our own risk to the address given on this Application Form (except where I/we have applied for 1,000,000 or more H Shares and have indicated on this Application Form that I/we wish to collect any refund cheques in person in accordance with the procedure prescribed in this Application Form and the Prospectus);
- have read the terms and conditions and application procedures set out in this Application Form and in the Prospectus and agree to be bound by them, and are aware of the restrictions on the Hong Kong Public Offering described in the Prospectus;
- represent, warrant and undertake that I/we understand that the H Shares have not been and will not be registered under the U.S. Securities Act;
- represent, warrant and undertake that neither I/we nor the person(s) for whose benefit I am/we are applying for the H Shares is/are restricted by any applicable laws of Hong Kong or elsewhere from making the application, paying any application moneys for, or being allotted or taking up, any Hong Kong Offer Shares; and that I am/each of us, and each of the persons for whose benefit I am/we are applying is neither a U.S. person(s) nor a person inside the United States (both as defined in Regulation S under the U.S. Securities Act) when completing and submitting this Application Form, or I am/each of us, and each of the persons for whose benefit I am/we are applying is a person described in paragraph (h)(3) of Rule 902 of Regulation S under the U.S. Securities Act, and the allotment of or application for the Hong Kong Offer Shares to me/us or by me/us or for whose benefit this application is made would not require the Company to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong; and
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.

致: 上海醫藥集團股份有限公司
高盛(亞洲)有限責任公司
德意志銀行香港分行
瑞士信貸(香港)有限公司
香港承銷商

本人/我們:

- 按照招股說明書及本申請表格的條款及條件,並依據章程規定,申請認購以下數目的香港發售股份;
- 隨附申請香港發售股份所需全數款項(包括1%經紀佣金、0.003%證監會交易費及0.005%香港聯交所交易費);
- 承諾及同意接納本人/我們根據本申請所申請認購的香港發售股份,或獲分配的任何較少數目的香港發售股份;
- 聲明此項認購申請乃以本人/我們或本人/我們代為申請的人士為受益人以白色或黃色申請表格,或透過中央結算系統向香港結算及/或根據白表eIPO服務(www.eipo.com.hk)向指定白表eIPO服務供應商發出電子認購指示作出及擬作出的唯一認購申請;
- 承諾及確認本人/我們及本人/我們為其利益作出認購申請的人士並無申請、接納或表示有意認購或收取或獲配售或分配(包括有條件及/或暫定),亦不會申請、接納或表示有意認購國際發售的任何國際發售股份;
- 明白貴公司及聯席承銷商將倚賴本聲明及陳述,以決定是否就本申請分配任何香港發售股份,倘若本人/吾等作出虛假聲明,則或會受檢控;
- 授權貴公司將香港結算代理人的名稱列入貴公司股東名冊內,登記為任何將分配予本人/我們的香港發售股份的持有人,並將有關H股股票直接存入中央結算系統,以按本人/我們的指示寄存於本人/我們的中央結算系統投資者戶口持有人股份戶口或本人/我們指定的中央結算系統參與者股份戶口;
- 要求任何退款支票以本人/吾等或本人/吾等代為其利益作出認購申請的人士為抬頭人,並在(符合本申請表格及招股說明書所載的條款及條件的情況下)按本申請表格上所示地址以平郵方式寄發任何退款支票,郵誤風險概由本人/我們承擔(我們已申請1,000,000股或以上的H股,並於本申請表格上表明擬按本申請表格及招股說明書所述程序親自領取任何退款支票則除外);
- 已細閱本申請表格及招股說明書所載的條款、條件及申請程序,並願受其約束,且知悉招股說明書所載的香港公開發售限制;
- 申明、保證及承諾本人/吾等及本人/吾等為其利益作出認購申請的人士提出申請、支付任何申請股款、獲分配或認購任何香港發售股份,不受香港或其他地方適用的法律限制;且本人/我們及本人/我們為其利益提出認購申請的各名人士在填寫及遞交申請表格之時並非美國人士,亦非身處美國境內的人士(兩者定義見美國證券法S規則)或本人/我們中的任何一人、及本人/我們為其利益提出申請的任何人士均非美國證券法規則902條所述之人士,及本人/我們或本人/我們為其利益提出認購申請的人士獲分配或申請香港發售股份不會引致貴公司須從香港以外任何地區的任何法律或法規的任何規定(不論是具法律效力);及
- 同意本申請、任何對本申請的接納及因此訂立的合同均受香港法律規管及按其詮釋。

For Broker use 此欄供經紀填寫 Lodged by 申請由以下經紀遞交

Broker No. 經紀號碼					
Broker's Chop 經紀印章					

Signed by (all) applicant(s) (all joint applicants must sign):
由(所有)申請人簽署(所有聯名申請人均須簽署):

Date: 日期: / /
D 日 M 月 Y 年

Warning:

- It is important that you read the terms and conditions and application procedures overleaf.
- You must sign this Application Form. If you do not sign this Application Form, otherwise this application is liable to be rejected.
- All applicable boxes in this Application Form must be completed, otherwise the application is liable to be rejected.
- It is important that you follow the application procedures on the overleaf, otherwise the Company reserves the right to reject the application.
- You must complete this Application Form in English unless as stated otherwise, otherwise the application is liable to be rejected.
- Only one application may be made for the benefit of any person on a WHITE or YELLOW Application Form or by way of giving electronic application instructions to HKSCC via CCASS or to the designated White Form eIPO Service Provider under the White Form eIPO service (www.eipo.com.hk). Multiple or suspected multiple applications on WHITE and/or YELLOW Application Forms and/or by way of giving electronic application instructions to HKSCC via CCASS and/or to the designated White Form eIPO Service Provider under the White Form eIPO service (www.eipo.com.hk) applications made by one applicant on either a WHITE or YELLOW Application Form or by way of giving electronic application instructions to HKSCC via CCASS and/or to the designated White Form eIPO Service Provider under the White Form eIPO service (www.eipo.com.hk) for more than 16,605,400 Hong Kong Offer Shares, being 50% of the Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, and applications where cheques or banker's cashier orders are dishonoured upon first presentation are liable to be rejected.
- You may be prosecuted if you make a false declaration.

警告:

- 閣下務必細閱背頁所載條款及條件以及申請程序。
- 閣下必須親筆簽署本申請表格,不得以個人印章代替,否則申請會遭拒絕受理。
- 本申請表格所有適用部分必須填妥,否則申請會遭拒絕受理。
- 閣下必須遵守背頁的申請程序,否則本公司保留拒絕受理有關申請的權利。
- 閣下必須以英文填寫本申請表格(除非另有指明),否則申請會遭拒絕受理。
- 僅能以白色或黃色申請表格或透過中央結算系統向香港結算或根據白表eIPO服務(www.eipo.com.hk)向指定白表eIPO服務供應商發出電子認購指示以受各人身作出一項認購申請,或以白色或黃色申請表格及/或透過中央結算系統向香港結算及/或根據白表eIPO服務(www.eipo.com.hk)向指定白表eIPO服務供應商發出電子認購指示作出的重覆或疑屬重覆申請,由一名申請人以白色或黃色申請表格或透過中央結算系統向香港結算及/或根據白表eIPO服務(www.eipo.com.hk)向指定白表eIPO服務供應商發出電子認購指示提出認購超過16,605,400股香港發售股份(即香港公開發售下初步發售可供認購的香港發售股份的50%)的認購申請,及支票或銀行本票於首次遞交時不獲兌現的申請,均可遭拒絕受理。
- 閣下如作出虛假聲明,可能會被檢控。

* For identification purposes only

• 僅供識別

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited ("HKSCC Nominees") and deposited directly into the Central Clearing and Settlement System ("CCASS") for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant.

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份,並直接存入中央結算及交收系統(「中央結算系統」),以寄存於閣下的中央結算系統投資者戶口持有入股份戶口或閣下指定的中央結算系統參與者股份戶口,請用本表格。

Number of Hong Kong Offer Shares applied for, not to exceed 16,605,400 Hong Kong Offer Shares, being 50% of the Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering
申請認購香港發售股份數目(不得超過16,605,400股香港發售股份,即香港公開發售項下初步提呈可供認購的香港發售股份的50%)

--

Cheque/banker's cashier order number
支票/銀行本票號碼

--

Total amount of payment
付款總額

HK\$	港元
------	----

Name of bank on which cheque/banker's cashier order is drawn*
支票/銀行本票的付款銀行名稱*

--

* Cheque and banker's cashier order should be crossed "Account Payee Only" and made payable to "Bank of Communications (Nominee) Co. Ltd. - Shanghai Pharma Public Offer".

* 支票及銀行本票須以劃線註明「只准入抬頭人賬戶」方式開出,並須註明抬頭人為「交通銀行(代理人)有限公司-上海醫藥公開發售」。

To be completed in BLOCK letters in English in ink, except as stated otherwise. Joint applicants should give the address of the first-named applicant only. 除另有說明外,請用墨水筆以英文正楷填寫。聯名申請人只須填寫排名首位申請人的地址。

Your name (in English)
英文姓名/名稱

Family name or company name 姓氏或公司名稱	Forename(s) 名字
-------------------------------------	----------------

Your name (in Chinese)
中文姓名/名稱

Family name or company name 姓氏或公司名稱	Forename(s) 名字
-------------------------------------	----------------

Your occupation (in English)
職業(以英文填寫)

--

Your Hong Kong identity card No./Passport No./Hong Kong business registration No. **
(Please delete as appropriate)
閣下的香港身份證號碼/護照號碼/香港商業登記號碼**
(請刪除不適用者)

--

Name of all other joint applicants (in English) (if any)
所有其他聯名申請人的英文姓名/名稱(如有)

(1)
(2)
(3)

Hong Kong identity card No./Passport No./Hong Kong business registration No. of all other joint applicants**
(Please delete as appropriate)
所有其他聯名申請人的香港身份證號碼/護照號碼/香港商業登記號碼**
(請刪除不適用者)

(1)
(2)
(3)

Your address in English (Joint applicants should give the address and telephone number of the first-named applicant only) Only an address in Hong Kong will be accepted
閣下的地址(以英文填寫)(聯名申請人只須填寫排名首位申請人的地址及電話號碼)只接受香港地址

Tel. no. 電話號碼

For nominees: Please provide an account number or identification code for each (joint) beneficial owner.
由代名人遞交:請填寫各(聯名)實益擁有人的賬戶號碼或身份識別編碼。

--

If you are a nominee and you do not complete this section, this application will be treated as being made for your own benefit. The account number(s) or identification code(s) for each (joint) beneficial owner must be provided.

如閣下為代名人且並無填妥本節,則是項申請將被視為閣下本身利益提出,必須提供各(聯名)實益擁有人的賬戶號碼或身份識別編碼。

- ** (1) If you are a CCASS Investor Participant, only a Hong Kong identity card number (if you are an individual) or a Hong Kong business registration number (if you are a body corporate) will be accepted for this application. Please see paragraph 2 under the section "How to make your application" overleaf.
如閣下屬中央結算系統投資者戶口持有人,則是項申請只會接納香港身份證號碼(如閣下屬個人人士)或香港商業登記號碼(如閣下屬法人團體)。請參閱背頁「申請手續」一節第2段。
- (2) If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): For an individual, you must provide your Hong Kong identity card number or passport number. If you hold a Hong Kong identity card, please provide that number. If you do not hold a Hong Kong identity card, please provide your passport number. For a body corporate, please provide your Hong Kong business registration number. The Hong Kong identity card/Passport/Hong Kong business registration number will be used for checking the validity of Application Forms and otherwise for processing the application for H Shares and such data would be transferred to a third party for the accomplishment of such purposes.
如閣下透過指定的中央結算系統參與者(中央結算系統投資者戶口持有人除外)提出申請:如屬個人人士,閣下必須填寫閣下的香港身份證號碼或護照號碼。如閣下持有香港身份證,請填寫香港身份證號碼;否則,請填寫護照號碼。如屬法人團體,請填寫香港商業登記號碼。香港身份證/護照/香港商業登記號碼將用以核實申請表格是否有效及處理H股的申請,為此,該等資料將轉交予第三方以供核實之用。
- (3) Part of your Hong Kong identity card number/passport number, or if you are joint applicants, part of the Hong Kong identity card number/passport number of the first-named applicant, provided by you, may be printed on your refund cheque (if any). Such data will be used for checking the validity of Application Forms and such data would also be transferred to a third party for such purpose and refund purpose. Your banker may require verification of your Hong Kong identity card number/passport number before encashment of your refund cheque. Inaccurate completion of your Hong Kong identity card number/passport number may lead to delay in encashment of or may invalidate your refund cheque.
閣下所提供的香港身份證號碼/護照號碼的一部分,或如屬聯名申請人,則排名首位申請人的香港身份證號碼/護照號碼的一部分,或會列印在退款支票(如有)上。有關資料將用以核實申請表格是否有效,該等資料亦會轉交予第三方以供核實和退款之用。閣下的退款支票前,要求核實閣下的香港身份證號碼/護照號碼。未有準確填妥閣下的香港身份證號碼/護照號碼,或會導致退款支票延遲兌現或無效。
- (4) All joint applicants must give (if they are individuals) their Hong Kong identity card numbers or, where applicable, passport numbers, or (if they are bodies corporate) their Hong Kong business registration numbers. All applicants who have applied for 1,000,000 or more Hong Kong Offer Shares and wish to collect refund cheque(s) (where relevant) in person from the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong on the date of collection of refund cheque(s) (where relevant) which is expected to be on Thursday, May 19, 2011, should mark '✓' in the box on the left. Please refer to the section headed "How to Apply for Hong Kong Offer Shares - Dispatch/Collection of H Share Certificates and Refund Monies" in the Prospectus for more information.
所有聯名申請人必須提供(如屬個人人士)其香港身份證號碼或護照號碼(如適用),或(如屬法人團體)其香港商業登記號碼。

凡申請1,000,000股或以上香港發售股份,並擬親身於領取退款支票(如適用)當日(預計為2011年5月19日(星期四)前往本公司的H股證券登記處香港中央證券登記有限公司(地址為香港灣仔皇后大道東183號合和中心17樓1712-1716室)領取退款支票(如適用)的申請人,請在左方空格內填上「✓」號。有關詳情請參閱招股說明書「如何申請認購香港發售股份-發送/領取H股股票和退款」一節。

DETAILS FOR CCASS PARTICIPANT 中央結算系統參與者資料詳情

THIS BOX MUST BE DULY COMPLETED
此空格必須妥為填寫

Participant I.D. of the designated CCASS Participant or CCASS Investor Participant
指定中央結算系統參與者或中央結算系統投資者戶口持有人的參與者編號

For designated CCASS Participant or Corporate CCASS Investor Participant, please also affix the company chop bearing its company name.
指定中央結算系統參與者或公司中央結算系統投資者戶口持有人請加蓋顯示公司名稱的公司印章。

(See paragraph 2 under section "How to make your application" overleaf)
(請參閱背頁「申請手續」一節第2段)

For Bank use 此欄供銀行填寫

ADDRESS LABEL 地址標貼

Please repeat your name(s) and address as set out above in BLOCK letters
請用正楷字母填寫上表所示姓名/名稱及地址

Name(s) 姓名/名稱
Address 地址

閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份,並直接存入中央結算及交收系統(「中央結算系統」),以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口,請用本表格。

倘刊登招股說明書的任何補充文件,已提交申請的申請人可能會亦可能不會(視乎補充文件所載內容而定)接獲該等有關申請的通知。如果申請人未接獲通知,或申請人接獲通知並非根據所通知的期限申請,則所提交的一切申請將維持有效並可獲接納。除上文所述者外,申請一經提交即不可撤銷,且申請人將被視為根據招股說明書的招股說明書作出申請。

閣下的申請一經接納,即可不可撤銷或撤回。就此而言,於公告中公佈分配結果即構成對未獲接納的申請的接納,且不可退還。如果有關分配結果受若干條件規限或訂明以抽籤形式分配,則申請接納後與否會視乎有關條件能否達成或抽籤結果而定。

3. 有關香港交易所上市委員會在下列期間未批准H股上市,則分配予閣下或香港結算代理人的香港發售股份(如有)將作廢:
• 由截止辦理認購申請登記起計三星期內;或
• 截止辦理申請登記後六個月內。

4. 閣下根據香港公開發售及國際發售提出申請,閣下的申請將被拒絕:
• 閣下的申請為重複或疑屬重複申請;
• 申請的股份數目並非本申請表格一覽表所列的其中一個數目;

退還 閣下的款項
倘閣下基於上述任何原因未能收取任何香港發售股份,本公司將閣下的申請股款(連同1%經紀佣金、0.003%證監會交易徵費及0.005%香港聯交所交易費),不計利息退還予閣下。

預期發送日期為2011年5月19日(星期四)
閣下為選擇親自領取退還款項的個人申請人,則閣下不可授權任何其他人士代表閣下領取。閣下必須於領取退還款項時出示身份證明文件(必須為香港中央證券登記有限公司所接受的身份證明文件)。

申請手續

1. 按照下表計算閣下擬認購的香港發售股份數目應付的認購申請款項。閣下申請認購的股數最少為100股香港發售股份。申請認購股數須為下表所列的其中一個數目。申請任何其他數目香港發售股份概不會獲接受且該等申請或申請將被拒絕。閣下亦列出申請認購有關香港發售股份數目(最多16,605,400股香港發售股份)的應付股款總額。閣下須於申請認購時每股香港發售股份26.00港元的最高發售價格,另加1%經紀佣金、0.003%證監會交易徵費及0.005%香港聯交所交易費,下表載列申請認購若干香港發售股份數目的應繳股款總額以及閣下最多可申請認購香港發售股份數目。

3. 閣下的股票或銀行本票須緊繫於本申請表格上。閣下必須以一張支票或一張銀行本票支付所認購香港發售股份的股款。每份申請均須附帶一張支票或一張銀行本票。
如以支票付款,該支票必須:
• 由閣下在香港開設的港元銀行賬戶開出;
• 顯示閣下的賬戶名稱,而該賬戶名稱必須預印在支票上,或由有關銀行授權簽署的人士在該支票背面書寫。該賬戶名稱必須與閣下姓名相同。如屬聯名申請,則該賬戶名稱必須與排名首位申請人的姓名相同;

如閣下未在指定領取時間內親自領取退還款項,則退還款項將會以平郵方式寄往在本申請表格上所示地址,郵誤風險概由閣下承擔。閣下申請認購1,000,000股以下香港發售股份或倘閣下申請認購1,000,000股或以上香港發售股份,惟無在中請表格上表明親自領取退還款項,則閣下的退還款項將於發送日期(預期將為2011年5月19日(星期四))以平郵方式寄往閣下申請表格上所示地址,郵誤風險概由閣下承擔。

個人資料
個人資料收集聲明
個人資料(私隱)條例(「條例」)的主要條款已於1996年12月20日在香港生效。此項個人資料收集聲明是向H股申請人和持有人說明有關本公司及其H股證券登記處在個人資料和條例方面的政策和慣例。

1. 收集 閣下個人資料的原因
證券申請人或證券登記持有人以本身名義申請認購證券或轉讓或受讓證券時或尋求H股證券登記處的服務時,須不時向本公司或其代理人及H股證券登記處提供其最新的準確個人資料。未能提供所要求的資料可能導致閣下申請證券遭拒絕或延遲,或本公司或其H股證券登記處無法落實轉讓或提供服務,亦可能妨礙或延遲登記轉讓。閣下成功申請的香港發售股份及/或奇發H股股票及/或奇發閣下應得的退還款項。

3. 向他人轉交個人資料
本公司及其H股證券登記處會將證券持有人的個人資料保密,但本公司及其H股證券登記處可能會作出他們認為必要的查詢以確定個人資料的準確性以達到上述任何目的,尤其為他們可向或從下列任何及全部人士和實體或與下列任何及全部人士和實體互相披露、取閱或轉送(無論在香港境內或境外)證券持有人的個人資料:

4. 查閱及更正個人資料
條例規定,申請人及證券持有人有權確定本公司及/或H股證券登記處是否持有其個人資料,並有權索取有關該資料的副本並更正任何不準確資料。根據條例,本公司及H股證券登記處有權就處理任何查閱資料的要求收取合理的費用。所有查閱資料或更正資料的要求或查詢有關資料及持有資料種類的要求,均須通過招股說明書「公司資料」一節所披露或不時按適用法例獲知會的本公司註冊辦事處送交本公司聯席公司秘書或(視乎情況而定)通過H股證券登記處送交私隱監管人員。

(b) 中國銀行(香港)有限公司

Table with 3 columns: 分行名稱, 分行地址. Lists branches in Hong Kong including 中銀大廈分行, 九龍黃大仙分行, 新界屯門市康樂分行, 香港島中環德輔道分行, 九龍尖沙咀分行, 新界沙田中心分行.

(c) 渣打銀行(香港)有限公司

Table with 3 columns: 分行名稱, 分行地址. Lists branches in Hong Kong including 中環德輔道分行, 九龍尖沙咀分行, 新界沙田中心分行. Includes a schedule for application times from 2011年5月6日 to 2011年5月12日.

可供申請認購股份數目及應繳款項

Table with 8 columns: 申請認購的香港發售股份數目, 申請時應繳款項(港元), 申請認購的香港發售股份數目, 申請時應繳款項(港元), 申請認購的香港發售股份數目, 申請時應繳款項(港元), 申請認購的香港發售股份數目, 申請時應繳款項(港元).

(1) 閣下可申請的香港發售股份最高數目。